VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company, which recently began trading on the NASDAQ Capital Market under the ticker VRXA, is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results indicate potential for reducing off-target toxicity, a common challenge in conventional ADC therapies.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The BiTAC-ADC platform is one of several technologies the company is advancing as it expands its next-generation cancer therapy pipeline.
“The precision of our BiTAC technology could represent a significant step forward in the treatment of solid tumors,” said a company spokesperson. “We are eager to engage with potential partners at BIO 2026 to explore how this platform can be integrated into broader therapeutic strategies.”
The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the convention. The company’s recent listing on NASDAQ provides it with additional visibility and access to capital markets to support further development of its pipeline.
VERAXA Biotech is an emerging leader in designing novel cancer therapies. The company’s focus on improving the selectivity and efficacy of antibody-based treatments aims to address significant unmet needs in oncology. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties as detailed in the company’s filings with the SEC, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All parties undertake no duty to update this information unless required by law.
